This Beaten-Down Stock Just Jumped By 8%. Time to Buy?

The past 18 months have been challenging for Novo Nordisk (NYSE: NVO). Clinical setbacks, worse-than-expected financial results, and a loss of market share in its most important therapeutic area have all contributed to a significant stock price decline over this period. Is the bleeding over?Recent regulatory developments in the U.S. jolted Novo Nordisk's share price by as much as 8% in one day. Let's find out what happened and whether Novo Nordisk is worth investing in.Novo Nordisk generates the majority of its revenue from its GLP-1 products, which are approved for the treatment of diabetes, weight management, and several other conditions, including reducing the risk of major cardiovascular events. One of the company's most famous brands is Wegovy, an anti-obesity medicine. Wegovy is administered subcutaneously once a week.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool